{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:13:39Z","timestamp":1783944819120,"version":"3.55.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Rates of overweight and obesity are higher in patients suffering from psychiatric disorders than in the general population. Body composition and enzyme functions are affected by overweight, and consequently, the pharmacokinetics of drugs may vary in overweight patients. Thus, overweight and obesity are important factors in psychiatric disorders and their treatment. This analysis aimed to investigate the impact of body mass index (BMI) on serum concentrations of the antidepressant drugs amitriptyline, doxepin, escitalopram, mirtazapine, and venlafaxine, and the antipsychotic drugs clozapine, quetiapine, and risperidone, taking into account the following confounding parameters: age, sex, and smoking habit.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Inpatients and outpatients (N = 1657) who took at least one of the target drugs were included in this retrospective analysis. Serum concentrations of the target drugs and their metabolites were determined at the Department of Psychiatry, Psychosomatics, and Psychotherapy of the University Hospital of W\u00fcrzburg during routine therapeutic drug monitoring (January 2009\u2013December 2010), which was performed in the morning (trough level) at steady state.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Dose-corrected serum concentrations (CD) of the active moiety of doxepin and venlafaxine and of O-desmethylvenlafaxine were negatively associated with BMI (partial Pearson correlation, R = \u22120.267, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.002; R = \u22120.206, <jats:italic toggle=\"yes\">P<\/jats:italic> \u2264 0.001; R = \u22120.258, <jats:italic toggle=\"yes\">P<\/jats:italic> \u2264 0.001), and the CDs were different in normal weight, overweight, and obese patients (analysis of covariance, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.004, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001, <jats:italic toggle=\"yes\">P<\/jats:italic> \u2264 0.001). No association was found between BMI and serum concentrations of amitriptyline, escitalopram, mirtazapine, clozapine, quetiapine, and risperidone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In obese patients, higher doses of doxepin and venlafaxine are necessary to achieve similar serum concentrations as in normal weight patients and to avoid treatment-resistant depression.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000812","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T22:49:55Z","timestamp":1599691795000},"page":"286-291","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Impact of Body Mass Index on Serum Concentrations of Antidepressants and Antipsychotics"],"prefix":"10.1097","volume":"43","author":[{"given":"Bodo","family":"Warrings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Samanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Deckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Unterecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Scherf-Clavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pnpbp.2013.05.005","article-title":"Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment","volume":"45","author":"Lopresti","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1177\/1359105308095977","article-title":"Does depression cause obesity?: a meta-analysis of longitudinal studies of depression and weight control","volume":"13","author":"Blaine","year":"2008","journal-title":"J Health Psychol."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.biopsych.2006.10.001","article-title":"Overweight and obesity affect treatment response in major depression","volume":"62","author":"Kloiber","year":"2007","journal-title":"Biol Psychiatry."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jad.2006.08.027","article-title":"BMI, sex, and antidepressant response","volume":"99","author":"Khan","year":"2007","journal-title":"J Affect Disord."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jad.2009.02.013","article-title":"Body weight as a predictor of antidepressant efficacy in the GENDEP project","volume":"118","author":"Uher","year":"2009","journal-title":"J Affect Disord."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1017\/S1461145704004602","article-title":"Obesity among outpatients with major depressive disorder","volume":"8","author":"Papakostas","year":"2005","journal-title":"Int J Neuropsychopharmacol."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"144","DOI":"10.5507\/bp.2017.026","article-title":"Effects of obesity on liver cytochromes P450 in various animal models","volume":"161","author":"Tomankova","year":"2017","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","article-title":"Impact of obesity on drug metabolism and elimination in adults and children","volume":"51","author":"Brill","year":"2012","journal-title":"Clin Pharmacokinet."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00003088-199325020-00003","article-title":"Clinical pharmacokinetics of drugs in obesity. An update","volume":"25","author":"Cheymol","year":"1993","journal-title":"Clin Pharmacokinet."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-200039030-00004","article-title":"Effects of obesity on pharmacokinetics implications for drug therapy","volume":"39","author":"Cheymol","year":"2000","journal-title":"Clin Pharmacokinet."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00702-014-1317-9","article-title":"Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI","volume":"122","author":"Sigurdsson","year":"2015","journal-title":"J Neural Transm (Vienna)."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.psyneuen.2016.07.009","article-title":"Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis","volume":"73","author":"Paulzen","year":"2016","journal-title":"Psychoneuroendocrinology."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/FTD.0b013e318237b0fa","article-title":"No influence of body weight on serum levels of antidepressants","volume":"33","author":"Unterecker","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1055\/s-0031-1301366","article-title":"The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions","volume":"45","author":"Unterecker","year":"2012","journal-title":"Pharmacopsychiatry."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00003088-200038060-00001","article-title":"Clinical pharmacokinetics of mirtazapine","volume":"38","author":"Timmer","year":"2000","journal-title":"Clin Pharmacokinet."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/JCP.0000000000001080","article-title":"Smoking is associated with lower dose-corrected serum concentrations of escitalopram","volume":"39","author":"Scherf-Clavel","year":"2019","journal-title":"J Clin Psychopharmacol."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/acps.12794","article-title":"Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine","volume":"136","author":"Castberg","year":"2017","journal-title":"Acta Psychiatr Scand."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/YIC.0000000000000250","article-title":"Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2","volume":"34","author":"Scherf-Clavel","year":"2019","journal-title":"Int Clin Psychopharmacol."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry","volume":"37","author":"Baumann","year":"2004","journal-title":"Pharmacopsychiatry."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/YIC.0000000000000234","article-title":"Sex and body weight are major determinants of venlafaxine pharmacokinetics","volume":"33","author":"Schoretsanitis","year":"2018","journal-title":"Int Clin Psychopharmacol."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00228-002-0448-3","article-title":"Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach","volume":"58","author":"Meyer-Barner","year":"2002","journal-title":"Eur J Clin Pharmacol."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/jps.2600760902","article-title":"Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design","volume":"76","author":"Hansch","year":"1987","journal-title":"J Pharm Sci."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/17425255.2020.1701653","article-title":"Modulation of expression\/function of intestinal P-glycoprotein under disease states","volume":"16","author":"Murakami","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01.ftd.0000158873.54100.d4","article-title":"Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study","volume":"27","author":"Reis","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00228-004-0737-0","article-title":"Population pharmacokinetic analysis of mirtazapine","volume":"60","author":"Grasmader","year":"2004","journal-title":"Eur J Clin Pharmacol."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2147\/NDT.S113099","article-title":"Antipsychotic-associated weight gain: management strategies and impact on treatment adherence","volume":"13","author":"Dayabandara","year":"2017","journal-title":"Neuropsychiatr Dis Treat."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"R30-20250603","first-page":"1102","article-title":"Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram","volume":"29","author":"von Moltke","year":"2001","journal-title":"Drug Metab Dispos."},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1081\/DMR-200033482","article-title":"The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in man","volume":"36","author":"Breyer-Pfaff","year":"2004","journal-title":"Drug Metab Rev."},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin Pharmacol Ther."},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/FPC.0000000000000003","article-title":"PharmGKB summary: venlafaxine pathway","volume":"24","author":"Sangkuhl","year":"2014","journal-title":"Pharmacogenet Genomics."},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0033-3182(10)70664-2","article-title":"The pharmacokinetics of paliperidone versus risperidone","volume":"51","author":"de Leon","year":"2010","journal-title":"Psychosomatics."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000812","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:26:28Z","timestamp":1748971588000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000812","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"2020-07-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}